An investigational PCSK9 inhibitor with a different mechanism from existing drugs in this class has been shown to safely and ...

New late-breaking clinical trial data presented at ACC and published simultaneously in JACC show benefit of investigational medicine AZD0780 on top of standard of care WILMINGTON, Del.--( ...

Positive results from the PURSUIT phase IIb trial for AstraZeneca’s AZD0780 demonstrated a statistically significant low-density lipoprotein cholesterol (LDL-C) reduction when administered on top of ...

AstraZeneca’s AZD0780 is an investigational oral medication that was developed to lower low-density lipoprotein cholesterol (LDL-C). It acts as a small molecule inhibitor of proprotein ...

At 12 weeks, AZD0780 30mg taken once-daily led to a 50.7% reduction in LDL-C. Similar efficacy was observed regardless of whether trial participants received moderate- or high- intensity statin ...

AstraZeneca's AZD0780 has demonstrated significant efficacy in a Phase IIb trial, showing a 50.7% reduction in LDL-C after 12 weeks when added to standard statin therapy. The treatment helped 84% ...

Results from the PURSUIT Phase IIb trial for AstraZeneca’s (AZN) AZD0780 demonstrated a statistically significant low-density lipoprotein cholesterol reduction when administered on top of ...

Positive results from the PURSUIT Phase IIb trial for AstraZeneca’s AZD0780 demonstrated a statistically significant low-density lipoprotein cholesterol (LDL-C) reduction when administered on ...

Results of the phase 2b PURSUIT study, which evaluated AZD0780 (AstraZeneca), an oral small molecule PCSK9 inhibitor, were presented at the American College of Cardiology Scientific Session.

The candidate in question, dubbed AZD0780, is an oral small molecule PCSK9 inhibitor in development for dyslipidemia, a condition characterized by elevated cholesterol in the blood that can ...